• 22 Views
  • 9 Downloads
Original Article
Egyptian Journal of Basic and Clinical Pharmacology
Vol. 7 (2017), Issue 1, pp. 47-56
doi:10.11131/2017/101364

Pentoxifylline and Cilostazol Against Rat Heart Injuries Induced by Doxorubicin

Noha A. T. Abbas and Soad L. Kabil

Department of Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, Egypt


Copyright © 2017 Noha A. T. Abbas and Soad L. Kabil. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We investigated the possible protective effects of pentoxifylline (PTX) and cilostazol on doxorubicin (Dox)-induced cardiotoxicity in rats. Rats are randomly assigned into: saline, Dox (I.P. 2.5 mg/kg every other day six injections over two weeks), Dox (I.P. 2.5 mg/kg every other day six injections over two weeks then PTX (50 mg/kg/day/oral), Dox (I.P. 2.5 mg/kg) every other day six injections over two weeks then cilostazol (50 mg/kg/day/oral). After 21 days these animals were sacrificed and serum CK-MB and troponin I levels were determined. Malondialdehyde (MDA), superoxide dismutase (SOD), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and caspase-3 levels also were determined. Heart sections were examinedhistopathologically. Treatment with PTX and cilostazol decreased troponin I and CK-MB while increased SOD activity with decrements in MDA, IL-6, TNF-α, and caspase-3 levels with attenuation of the changes in cardiac histopathology. PTX and cilostazol exert protective effects against Dox-induced cardiotoxicity.

Original Article
Egyptian Journal of Basic and Clinical Pharmacology
Vol. 7 (2017), Issue 1, pp. 47-56
doi:10.11131/2017/101364

Pentoxifylline and Cilostazol Against Rat Heart Injuries Induced by Doxorubicin

Noha A. T. Abbas and Soad L. Kabil

Department of Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, Egypt


Copyright © 2017 Noha A. T. Abbas and Soad L. Kabil. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We investigated the possible protective effects of pentoxifylline (PTX) and cilostazol on doxorubicin (Dox)-induced cardiotoxicity in rats. Rats are randomly assigned into: saline, Dox (I.P. 2.5 mg/kg every other day six injections over two weeks), Dox (I.P. 2.5 mg/kg every other day six injections over two weeks then PTX (50 mg/kg/day/oral), Dox (I.P. 2.5 mg/kg) every other day six injections over two weeks then cilostazol (50 mg/kg/day/oral). After 21 days these animals were sacrificed and serum CK-MB and troponin I levels were determined. Malondialdehyde (MDA), superoxide dismutase (SOD), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and caspase-3 levels also were determined. Heart sections were examinedhistopathologically. Treatment with PTX and cilostazol decreased troponin I and CK-MB while increased SOD activity with decrements in MDA, IL-6, TNF-α, and caspase-3 levels with attenuation of the changes in cardiac histopathology. PTX and cilostazol exert protective effects against Dox-induced cardiotoxicity.

Original Article
Egyptian Journal of Basic and Clinical Pharmacology
Vol. 7 (2017), Issue 1, pp. 47-56
doi:10.11131/2017/101364

Pentoxifylline and Cilostazol Against Rat Heart Injuries Induced by Doxorubicin

Noha A. T. Abbas and Soad L. Kabil

Department of Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, Egypt


Copyright © 2017 Noha A. T. Abbas and Soad L. Kabil. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Noha A. T. Abbas and Soad L. Kabil, “Pentoxifylline and Cilostazol Against Rat Heart Injuries Induced by Doxorubicin,” Egyptian Journal of Basic and Clinical Pharmacology, Vol. 7, Issue 1, pp. 47-56, 2017. doi:10.11131/2017/101364